Information card 

PhD
KATARZYNA KOLASA

Department of Health Economics and Healthcare Management

PhD KATARZYNA KOLASA

Publications
Articles in scientific journals:
  • KOLASA K., Zwolinski K., Zah V., Kaló Z., Lewandowski T. (2018), Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis, ORPHANET JOURNAL OF RARE DISEASES, online, s.1-14
  • KOLASA K., Kowalczyk M. (2017), The effects of payments for pharmaceuticals: a systematic literature review, HEALTH ECONOMICS POLICY AND LAW, online, s.1-18
  • KOLASA K., Kowalczyk M. (2016), Does cost sharing do more harm or more good? - a systematic literature review, BMC PUBLIC HEALTH, 16, s.1-14
  • KOLASA K., Zwolinski K., Hermanowski T. (2016), Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs, ORPHANET JOURNAL OF RARE DISEASES, 11, s.1-12
  • KOLASA K., Kaló Z., Zah V. (2016), The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations, EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 16(4), s.483-488
  • KOLASA K., Lewandowski T. (2015), Does it matter whose opinion we seek regarding the allocation of healthcare resources? - a case study, BMC HEALTH SERVICES RESEARCH, 15, s.1-10
  • KOLASA K., Kaló Z., Hornby E. (2015), Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices, EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 1, s.145-155
  • Hermanowski T., KOLASA K., Zawada A., Rybnik T., Rabczenko D., Cegłowska U. (2015), Inequity in Access to Health Care Services in Poland Compared to Denmark and Germany. Analysis of Data from the SHARE Study, POLITYKA SPOŁECZNA, 2(491), s.22-27
zobacz pozostałe publikacjeukryj pozostałe publikacje
  • KOLASA K. (2014), Are pricing and reimbursement decision-making criteria aligned with public preferences regarding allocation principles in the Polish healthcare sector?, EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 14(5), s.751-762
  • KOLASA K., Dohnalik J., Borek E., Siemiątkowski M., Ścibiorski C. (2014), The paradox of public participation in the healthcare in Poland – What citizens want, and what they think, HEALTH POLICY, 2, s.159-165
  • KOLASA K., Hermanowski T., Borek E. (2013), Importance of public participation in decision-making process in healthcare system illustarted with an example of the development of american and polish scope of health benefit basket, PRZEGLĄD EPIDEMIOLOGICZNY, 67, s.661-666
  • KOLASA K., Annemans L., Lees M. (2013), Attitudes toward supplementary criteria in the reimbursement process in Poland, INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 4, s.443-449
  • KOLASA K. (2013), How much is the cost of multiple sclerosis – systematic literature review, PRZEGLĄD EPIDEMIOLOGICZNY, 67, s.75-85
  • KOLASA K. (2013), Obiektywność decyzji refundacyjnych - czy zawsze musi się opłacać?, PRZEGLĄD EPIDEMIOLOGICZNY, 67, s.599-603
  • KOLASA K., Grzeszczak W., Czupryniak L., Sciborski C., Lomon I., McEwan P. (2012), The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland, DIABETES TECHNOLOGY & THERAPEUTICS, 14(1), s.65-73
  • KOLASA K., Wasiak R. (2012), Health technology assessment in poland and scotland: comparison of process and decisions, INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 1, s.70-76
  • KOLASA K., Rybnik T. (2012), Socio-demographic determinants of inequity of access to health care in Poland in 2011 – based on social diagnosis, PRZEGLĄD EPIDEMIOLOGICZNY, 66(4), s.681-688
  • KOLASA K. (2012), Współpłacenie za zdrowie - za i przeciw, POLITYKA SPOŁECZNA, 10(463), s.19-21
  • Gustavsson A., Brinck P., Bergvall N., KOLASA K., Wimo A., Winblad B., Jönsson L. (2011), Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients, Alzheimers & Dementia, 7(3), s.318-327
  • KOLASA K., Dziomdziora M., Fajutrao L. (2011), What aspects of the health technology assessment process recommended by international health technology assessment agencies received the most attention in Poland in 2008?, INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 1, s.84-94
  • KOLASA K., Lees M. (2011), PHP53 Assessment of the Attitudes of the General Public Towards Supplementary Criteria to Be Used in P&R Decision Making Process in Poland, VALUE IN HEALTH, 7, s.A342
  • KOLASA K., Schubert S., Hermanowski T. (2011), A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland, HEALTH POLICY, 102(2-3), s.145-151
Monographs:
  • KOLASA K. (2012), Optymalna alokacja zasobów w ochronie zdrowia, WOLTERS KLUWER POLSKA
Additional Information
Consultancy:
Straub Medical
GE Healthcare
Lundbeck
BiogenIdec
Bristol Myers Squibb
Bristol Myers Squibb, Warsaw and Stockholm
Astra Zeneca Global R&D